Edit
Synapse Biomedical
https://www.synapsebiomedical.com/?portfolioCats=34,23,29,35,22,24,30,25,28,31#new_tabLast activity: 23.12.2013
Active
Synapse Biomedical located in Oberlin OH about 30 miles west of Cleveland was established in 2002.
NeuRx Diaphragm Pacing System first received FDA approval for use in Spinal Cord Injury (SCI) patients. Dr Ray Onders, co-founder and developer of the technology recognized the benefits for ALS patients.
In 2011, the FDA approved, under a Humanitarian Device Exemption (HDE) the use of the NeuRx DPS in ALS patients with chronic hypoventilation.
To-date, over 1200 ALS and SCI patients have been successfully implanted and the DPS is used in 24 countries.
NeuRx Diaphragm Pacing System first received FDA approval for use in Spinal Cord Injury (SCI) patients. Dr Ray Onders, co-founder and developer of the technology recognized the benefits for ALS patients.
In 2011, the FDA approved, under a Humanitarian Device Exemption (HDE) the use of the NeuRx DPS in ALS patients with chronic hypoventilation.
To-date, over 1200 ALS and SCI patients have been successfully implanted and the DPS is used in 24 countries.
Location: United States, Ohio, Oberlin
Employees: 11-50
Phone: +1 440-774-2488
Total raised: $1.2M
Founded date: 2002
Investors 1
| Date | Name | Website |
| - | Vivo Capit... | vivocapita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.01.2010 | Series C | $1.2M | - |
Mentions in press and media 12
| Date | Title | Description |
| 23.12.2013 | Synapse Biomedical lands $2M | Synapse Biomedical said it landed $2.4 million in funding from the Ohio Third Frontier Commission for the next generation of its NeuRx technology. The NeuRx device is designed to provide electrical stimulation to the muscles and nerves of t... |
| 29.09.2011 | Synapse Biomedical gets FDA approval for ALS breathing system | The company’s NeuRx Diaphragm Pacing System electrically stimulates the diaphragm to contract, simulating a breathing motion, to help patients with inadequate breathing. The FDA approval applies to ALS patients who have stimulatable diaphra... |
| 14.01.2011 | Northeast Ohio attracts neurotech cluster | Cleveland Clinic neuromodulation spinoff Intelect Medical may have stealthily exited Cleveland to set up shop in Boston, but the company’s recent $78 million sale to Boston Scientific (NYSE:BSX) highlights Northeast Ohio’s growing strength ... |
| 13.01.2011 | A look at Northeast Ohio’s growing neurotechnology industry | Promoted Telemedicine’s potential to provide healthcare to the world’s most vulnerable Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| 12.10.2010 | Synapse wins FDA nod for ALS treatment | Synapse Biomedical Inc. received Humanitarian Use Device approval from the Food & Drug Administration for the company’s NeuRx Diaphragm Pacing System in certain ALS patients. Under the approval, the device that stimulates the diaphragm ... |
| 08.10.2010 | Synapse Biomedical gets FDA OK for diaphragm pacing device in ALS | Now, the FDA will review the company’s HDE application to determine whether NeuRx DPS is safe and has probable benefit for ALS patients who meet certain criteria. “We anticipate that the HDE initial review will take 75 days, although FDA qu... |
| 21.01.2010 | Synapse Biomedical aims to raise $1.2M to repay debt, prepare for ALS market | This breathing action enables patients to avoid the complications of mechanical ventilators, which force air into the lungs, causing a host of problems. The device can dramatically improve the quality of life for patients and slash costs ... |
| 21.01.2010 | Synapse Biomedical aims to raise $1.2 million in Series C round | By Mary Vanac OBERLIN, Ohio — Synapse Biomedical Inc. raised more than $433,000 from investors on its way to $1.2 million to repay debt and get ready to supply its diaphragm pacing technology to a new market: ALS patients. Launched in 2002,... |
| - | A look at Northeast Ohio’s growing neurotechnology industry | Cleveland Clinic neuromodulation spinoff Intelect Medical may have stealthily exited Cleveland to set up shop in Boston, but the company’s recent $78 million sale to Boston Scientific (NYSE: BSX) highlights Northeast Ohio’s growing strength... |
| - | Synapse Biomedical gets FDA approval for ALS breathing system | Neurotechnology company Synapse Biomedical has received Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and Drug Administration for a diaphragm pacing system that helps certain types of patients suffering from amyo... |
Show more